Skip to content

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Herpes study adds to understanding of viral reinfections, how to potentially prevent them

May 1, 2023
Immunology Infectious Disease
Basic Research
Grantee
Researchers in the laboratory.

In their lab, UIC researchers (left to right) Hemant Borase, Tejabhiram Yadavalli, Chandrashekhar Patil and Deepak Shukla. Photo courtesy of Deepak Shukla.

A new study on herpes infections of the eye from University of Illinois Chicago researchers helps shed light on the question of viral reinfections by identifying a key protein involved in viral reinfections that could be targeted by antiviral drugs.

The UIC team examined how the heparanase protein, which is present in all our cells, affects reinfection from the herpes simplex virus type 1 in mice. They found that inhibiting heparanase activity can protect the eyes from being reinfected. Mice that had their heparanase protein blocked showed no signs of cloudiness in their corneas after a second infection, as compared with mice with normal heparanase, whose corneas showed significant signs of reinfection.

Additionally, the researchers found that when the protein is activated due to infection, the immune system may exacerbate the symptoms during a second infection. The study, published recently in Science Advances, also discovered that when heparanase is malfunctioning, the virus is more likely to cause disease in individuals previously infected with the virus.

Taken together, the findings suggest that inhibiting the activity of the heparanase protein can be an effective way to prevent herpes simplex virus type 1 reinfection, potentially leading to a breakthrough in preventing the recurrence of these infections.